Amerisource Bergen Corp.


Market Cap$36.39B

Compare Amerisource Bergen

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Amerisource Bergen Corp.Amerisource Bergen Corp.21.51.07%246%0.17.3
marketMarket Avg49.61.28%30%6.11.1
IndustrialsIndustrials Avg19.10.99%21%3.10.6

Earnings Call Q2 2023

May 2, 2023 - AI Summary

AmerisourceBergen reported strong financial performance in Q2 FY2023, with revenue growth of nearly 10% and adjusted EPS growth of 9%.
The company's pharmaceutical-centric strategy and leadership in specialty distribution continue to drive its success, with a focus on enhancing oncology-focused practice solutions and services.
AmerisourceBergen recently announced an investment in OneOncology, a network of community oncologists, to deepen its ties to community providers and expand its capabilities in inventory management, practice analytics, and clinical trial support.
The company is leveraging its infrastructure and scale to increase efficiency and align its capabilities to customer needs, while also investing in new technologies and resources such as real-time location monitoring for pharmaceutical logistics.
AmerisourceBergen's recent acquisition of PharmaLex enhances its portfolio of solutions to support pharma manufacturers throughout the development process, including pharmacovigilance, regulatory affairs consulting, and clinical trial logistics.
The company raised its fiscal year 2023 guidance, expecting consolidated revenue growth of 6-8%, operating income growth of 2-4%, and diluted EPS of $11.70-$11.90, reflecting continued strength in the U.S. Healthcare Solutions segment and improved FX rates in the International Healthcare Solutions segment.

Current Fair Value

6.8% upside

Undervalued by 6.8% based on the discounted cash flow analysis.

Share Statistics

Market cap$36.39 Billion
Enterprise Value$40.02 Billion
Dividend Yield$1.9304 (1.07%)
Earnings per Share$8.19
Outstanding Shares202,174,856
Avg 30 Day Volume2,447,412


Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio21.54
Price to Sales0.14
Price to Book Ratio59.99
Enterprise Value to Revenue0.16
Enterprise Value to EBIT15.08
Enterprise Value to Net Income23
Total Debt to Enterprise0.13
Debt to Equity7.32

Revenue Sources

No data

ESG Score

No data

About Amerisource Bergen Corp.

22,000 employees
CEO: Steven Collis

AmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care. Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their part...